![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
RJ Solaro, P Bousquet and JD Johnson
We report that bepridil, a Ca++ channel blocker and calmodulin antagonist, which has been shown to enter myocytes, stimulates the mechanical and biochemical activity of cardiac myofilaments. Bepridil increased significantly the level of Ca++-dependent actomyosin Mg++- ATPase activity of myofibrils and the submaximal force developed by chemically skinned trabeculae of pig heart. In the range of concentrations (10-100 microM) in which bepridil showed this stimulatory activity, diltiazem and verapamil were without effect. The effect of bepridil on myofilament force and ATPase activity was higher at relatively low free Ca++ concentrations, and myofibrils lacking troponin-tropomyosin were not affected by bepridil. Associated with the stimulation of force and ATPase activity by bepridil was an increase in the amounts of Ca++ bound to troponin C (TnC). That bepridil stimulates TnC Ca++ binding was also shown in experiments using pure TnC labeled with 2-(4'-iodoacetamidoanilo)naphthalene-6-sulfonic acid, a fluorescent probe that reports Ca++ bound to the single "regulatory" site. Effects of bepridil on the fluorescence of a felodipine-cardiac TnC complex indicate that bepridil binds to TnC over the same range of doses where it affects myofilament activity. Our results indicate that the inotropic action of bepridil may result from a net response of heart cells to influences on the delivery of Ca++ to the myofilaments and their response to Ca++.
This article has been cited by other articles:
|
|
 |
|
  K. L. Kreutziger, N. Piroddi, B. Scellini, C. Tesi, C. Poggesi, and M. Regnier Thin filament Ca2+ binding properties and regulatory unit interactions alter kinetics of tension development and relaxation in rabbit skeletal muscle J. Physiol., August 1, 2008; 586(15): 3683 - 3700. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Davis and S. B. Tikunova Ca2+ exchange with troponin C and cardiac muscle dynamics Cardiovasc Res, March 1, 2008; 77(4): 619 - 626. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Pinto, M. S. Parvatiyar, M. A. Jones, J. Liang, and J. D. Potter A Troponin T Mutation That Causes Infantile Restrictive Cardiomyopathy Increases Ca2+ Sensitivity of Force Development and Impairs the Inhibitory Properties of Troponin J. Biol. Chem., January 25, 2008; 283(4): 2156 - 2166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Kass and R. J. Solaro Mechanisms and Use of Calcium-Sensitizing Agents in the Failing Heart Circulation, January 17, 2006; 113(2): 305 - 315. [Full Text] [PDF]
|
|
|
|
|
|
X. Wang, M. X. Li, and B. D. Sykes Structure of the Regulatory N-domain of Human Cardiac Troponin C in Complex with Human Cardiac Troponin I147-163 and Bepridil J. Biol. Chem., August 16, 2002; 277(34): 31124 - 31133. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Kleerekoper and J. A. Putkey Drug Binding to Cardiac Troponin C J. Biol. Chem., August 20, 1999; 274(34): 23932 - 23939. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Kleerekoper, W. Liu, D. Choi, and J. A. Putkey Identification of Binding Sites for Bepridil and Trifluoperazine on Cardiac Troponin C J. Biol. Chem., April 3, 1998; 273(14): 8153 - 8160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Lin, D. G. Dotson, and J. A. Putkey Covalent Binding of Peptides to the N-terminal Hydrophobic Region of Cardiac Troponin C Has Limited Effects on Function J. Biol. Chem., January 5, 1996; 271(1): 244 - 249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Li, M. L. Love, J. A. Putkey, and C. Cohen Bepridil opens the regulatory N-terminal lobe of cardiac troponin C PNAS, May 9, 2000; 97(10): 5140 - 5145. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
